Showing results (141-150 of 324) with videos related to
Sort By:
Pageof 33
ILAR Journal|February 6, 2013
Nucleus accumbens invulnerability to methamphetamine neurotoxicityDonald M Kuhn, Mariana Angoa-Pérez, David M ThomasAmerican Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|March 26, 2021
Disparities in Cancer Care: The Example of Sarcoma-In Search of Solutions for a Global IssueThierry Alcindor, Sinziana Dumitra, Karen Albritton, et al.European Journal of Human Genetics : EJHG|May 15, 2014
Connecting patients, researchers and clinical genetics services: the experiences of participants in the Australian Ovarian Cancer Study (AOCS)Ashley Crook, Loren Plunkett, Laura E Forrest, et al.Journal of Neurochemistry|April 16, 2008
Methamphetamine-induced neurotoxicity and microglial activation are not mediated by fractalkine receptor signalingDavid M Thomas, Dina M Francescutti-Verbeem, Donald M KuhnFASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|December 31, 2005
Gene expression profile of activated microglia under conditions associated with dopamine neuronal damageDavid M Thomas, Dina M Francescutti-Verbeem, Donald M KuhnAnnals of the New York Academy of Sciences|November 11, 2008
Dopamine disposition in the presynaptic process regulates the severity of methamphetamine-induced neurotoxicityDonald M Kuhn, Dina M Francescutti-Verbeem, David M ThomasJournal of Neurochemistry|December 20, 2007
The newly synthesized pool of dopamine determines the severity of methamphetamine-induced neurotoxicityDavid M Thomas, Dina M Francescutti-Verbeem, Donald M KuhnJournal of Neurochemistry|May 22, 2009
Increases in cytoplasmic dopamine compromise the normal resistance of the nucleus accumbens to methamphetamine neurotoxicityDavid M Thomas, Dina M Francescutti-Verbeem, Donald M KuhnAnnals of the New York Academy of Sciences|November 16, 2006
Dopamine quinones activate microglia and induce a neurotoxic gene expression profile: relationship to methamphetamine-induced nerve ending damageDonald M Kuhn, Dina M Francescutti-Verbeem, David M ThomasPlos One|February 2, 2013
Analysis of RAD51D in ovarian cancer patients and families with a history of ovarian or breast cancerElla R Thompson, Simone M Rowley, Sarah Sawyer, et al.Pageof 33